Charles Albright

Charlie was most recently Chief Scientific Officer at Editas Medicine where his research group advanced the pioneering CRISPR gene editing platform and medicines from program inception to Investigational New Drug (IND). He has led research activities at both biotech and big pharma companies across a range of therapeutic areas including neurology, neuromuscular, cardiovascular, ophthalmology, and oncology. Prior to that, he was Vice President, Genetically Defined Diseases and Genomics at Bristol-Myers Squibb Company, where he was responsible for developing the group’s strategy and building a pipeline of novel therapeutics with a focus on central nervous system (CNS) and cardiovascular rare diseases. Prior to his career in industry, Charlie held academic positions at Vanderbilt University and Whitehead Institute for Biomedical Research. Charlie received a B.S. in chemical engineering and a Ph.D. in biology from Massachusetts Institute of Technology.